Tempus AI (NASDAQ:TEM) Stock Price Up 2% – Time to Buy?

Tempus AI, Inc. (NASDAQ:TEM)’s stock price shot up 2% on Wednesday . The company traded as high as $56.46 and last traded at $52.06. 6,193,066 shares traded hands during mid-day trading, a decline of 33% from the average session volume of 9,221,391 shares. The stock had previously closed at $51.02.

Analyst Ratings Changes

TEM has been the topic of a number of analyst reports. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and raised their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Loop Capital decreased their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Bank of America upped their target price on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Needham & Company LLC reissued a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a research note on Tuesday, January 14th. Finally, Piper Sandler restated a “neutral” rating and issued a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $56.36.

Tempus AI Trading Up 0.4 %

The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The firm has a 50 day moving average price of $44.26 and a two-hundred day moving average price of $47.95.

Insider Activity at Tempus AI

In other Tempus AI news, major shareholder Bradley A. Keywell sold 265,000 shares of the stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $35.10, for a total value of $9,301,500.00. Following the completion of the sale, the insider now owns 15,218,365 shares of the company’s stock, valued at $534,164,611.50. This trade represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Eric P. Lefkofsky sold 85,788 shares of the business’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $53.39, for a total transaction of $4,580,221.32. Following the transaction, the chief executive officer now directly owns 5,771,787 shares in the company, valued at approximately $308,155,707.93. The trade was a 1.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,862,758 shares of company stock worth $79,585,675.

Institutional Investors Weigh In On Tempus AI

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. acquired a new stake in shares of Tempus AI during the third quarter valued at about $30,000. FNY Investment Advisers LLC acquired a new stake in Tempus AI during the 4th quarter valued at approximately $67,000. Vestor Capital LLC purchased a new stake in Tempus AI during the 3rd quarter worth approximately $153,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Tempus AI in the 4th quarter valued at approximately $178,000. Finally, Stifel Financial Corp acquired a new position in shares of Tempus AI in the 3rd quarter valued at approximately $218,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.